Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Next Previous
X
Search
Trial Profile

A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivanib alaninate (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 03 Jan 2024 Results of pooled analysis from CO.17 and CO.20 investigating transverse colon primary tumor location as a biomarker in mCRC, published in the Clinical Cancer Research
    • 21 Jan 2023 Results of pooled analysis of two studies (CO.17 and CO.20) assessing the predictive and prognostic features of transverse colon primary location, presented at the 2023 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results assessing the association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated patients (n=592) presented at the 2018 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top